Detail akcie India Gbl Cap online

Business Summary: IGC Pharma, Inc. is a clinical-stage company, which is engaged in developing treatments for Alzheimer’s disease. The Company’s flagship drug, IGC-AD1, is an investigational drug tackles agitation, a major burden for patients and caregivers by addressing neuroinflammation. The Company operates through two segments: Life Sciences Segment and Infrastructure Segment. Its TGR-63 has demonstrated its potential to disrupt the progression of Alzheimer’s by targeting Aß plaques, a key disease hallmark. The Company’s IGC-1C represents a potential breakthrough by targeting tau protein and neurofibrillary tangles, aiming to modify the disease course. Its IGC-M3 focuses on early intervention by inhibiting Aß plaque formation, potentially slowing cognitive decline. Its LMP is designed to target multiple hallmarks of Alzheimer’s disease, including Aß plaques and neurofibrillary tangles for a comprehensive therapeutic effect. It seeks to leverage artificial intelligence (AI) for Alzheimer's research.
Financial Summary: BRIEF: For the three months ended 30 June 2025, IGC Pharma Inc revenues increased 21% to $328K. Net loss decreased 33% to $1.6M. Revenues reflect Life Sciences segment increase from $272K to $656K. Lower net loss reflects General and administrative expenses - decrease of 27% to $1.2M (expense), Research and development expenses decrease of 4% to $851K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.03 to -$0.02.